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ABSTRACT
Background: Maternal micronutrient deficiencies are commonly
associated with clinical indicators of placental dysfunction.
Objective:We tested the hypothesis that periconceptional multiple-
micronutrient supplementation (MMS) affects placental function.
Design: We conducted a double-blind, randomized, placebo-controlled
trial of MMS in 17- to 45-y-old Gambian women who were menstruat-
ing regularly and within the previous 3 mo. Eligible subjects were pre–
randomly assigned to supplementation with the UNICEF/WHO/United
Nations University multiple micronutrient preparation (UNIMMAP) or
placebo on recruitment and until they reached their first antenatal check-
up or for 1 y if they failed to conceive. Primary outcome measures were
midgestational indexes of utero-placental vascular-endothelial function
[ratio of plasminogen-activator inhibitor (PAI) 1 to PAI-2 and mean
uterine-artery resistance index (UtARI)] and placental active transport
capacity at delivery [fetal to maternal measles antibody (MMA) ratio].
Results: We recruited 1156 women who yielded 415 pregnancies,
of which 376 met all of the inclusion criteria. With adjustment for
gestational age at sampling, there were no differences in PAI-1 to
PAI-2 or MMA ratios between trial arms, but there was a 0.02-unit
reduction in UtARI between 18 and 32 wk of gestation (95% CI:
20.03, 20.00; P = 0.040) in women taking UNIMMAP.
Conclusions: Placental vascular function was modifiable by pericon-
ceptional micronutrient supplementation. However, the effect was
small and supplementation did not further affect other variables of
placental function. This trial was registered at www.controlled-trials.
com as ISRCTN 13687662. Am J Clin Nutr 2015;102:1450–9.
Keywords: periconceptional, micronutrients, pregnancy, placenta,
Africa, birth weight, fetal growth
INTRODUCTION
Micronutrient malnutrition is a common, global public health
problem, particularly for women living in poverty (1). Poor-
quality diets, low in animal-sourced foods, can lead to composite
micronutrient deficiencies (2) and adverse pregnancy outcomes
(3). Previous attempts to attenuate these effects through multiple-
micronutrient supplementation (MMS)6 have resulted in modest
increases in birth weight but no consistent effect on maternal or
perinatal morbidity (4). However, previous studies may have
started MMS too late to effect substantial changes in pregnancy
outcomes. The periconceptional period (before conception and
up to 12 wk of gestation) is arguably the optimal exposure
window for nutritional interventions because it encompasses
several critical gestational processes including implantation and
placentation (6). A recent systematic review identified only 9
micronutrient trials that specifically targeted the periconcep-
tional period and most were designed to investigate the impact
of supplementation on the incidence of birth defects (5). The
effect of early pregnancy micronutrient supplementation on the
developing placenta has been largely ignored.
The placenta is a complex endocrine organ integral to the
regulation of materno-fetal metabolism, physiology, and growth
(7). Placental vascularization during the first half of pregnancy
defines later placental transfer capacity and ultimately the fetal
growth trajectory and pregnancy outcome (8). This early period
of placental angiogenesis is characterized by strictly regulated
oxidative stress and inflammation, endothelial remodeling, and
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rapid cell turnover (9). Inadequate maternal and/or fetal micro-
nutrient supply could compromise any of these processes, impairing
angiogenesis and leading to placental dysfunction, fetal growth
restriction (FGR), and preterm birth (PTB) (10).
Several micronutrients have been implicated in shaping pla-
cental function, especially folic acid, vitamin D, antioxidant
vitamins, calcium, and iron (11). The mechanisms of action are
largely speculative but include molecular roles for several
micronutrients in the control of free radical production in hypoxic
early-placenta vasculature (10). Yet, it is unlikely that a single-
nutrient intervention will improve placental function and fetal
growth in most pregnancies, especially where combined de-
ficiencies are common. On the contrary, the need for a more
balanced, composite approach is evidenced by the finding that
universal folic acid supplementation of pregnant women in
areas where vitamin B-12 deficiency is common may program
diabetes risk in children (12). We conducted a randomized,
double-blinded, placebo-controlled trial of periconceptional
MMS in rural Gambian women to test the hypothesis that
periconceptional micronutrient status modulates placental function
in later pregnancy.
METHODS
Study design
The study was a double-blind, randomized, placebo-controlled
trial of periconceptional MMS assessed on 3 primary outcomes.
The first was the ratio of maternal plasminogen activation in-
hibitor (PAI) 1 (a marker of endothelial activation) to PAI-2 (a
marker of placental function) at 18–22 wk of gestation (13). In
a healthy pregnancy, the concentrations of both biomarkers
should increase progressively, but their ratio should decline as
placental mass, and PAI-2 production, increases (14).
The second primary outcome was uterine-artery Doppler wave-
form at 18–22 wk of gestation [a surrogate marker of placental
perfusion that correlates with trophoblast invasion (15)]. The
uterine-artery pulsatility index (UtAPI) and uterine-artery re-
sistance index (UtARI) were also measured at 28–32 wk of
gestation, and diastolic notching was noted. These indexes
quantify systolic and diastolic components of the flow velocity
waveform in a specific blood vessel over a single cardiac cy-
cle. The higher the values, the greater the downstream vascular
resistance. The third primary outcome was the ratio of the
delivery concentrations of fetal to maternal measles antibody
(MMA), which was used as a proxy marker of placental trans-
port capacity.
Intervention
The micronutrient supplement (Lomapharm) was a coated tab-
let containing 15 vitamins and trace elements, formulated to a
composition specified by the UNICEF/WHO/United Nations
University (UNICEF/WHO/UNU) for use by pregnant women in
the developing world and known as the UNICEF/WHO/UNU
international multiple micronutrient preparation (UNIMMAP)
(16). UNIMMAP contains the following: vitamin A (800 retinol
equivalents), vitamin D (200 IU), vitamin E (10 mg), vitamin C
(70 mg), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg),
pyridoxine (1.9 mg), cobalamin (2.6 mg), folic acid (400 mg),
iron (30 mg), zinc (15 mg), copper (2 mg), selenium (65 mg),
and iodine (150 mg). The placebo was manufactured to be in-
distinguishable from the supplement (Lomapharm).
Study setting
The study took place between March 2006 and June 2008 in
the Kiang West region of The Gambia among 33 villages under
demographic surveillance by the United Kingdom Medical Re-
search Council (MRC) field station staff at Keneba. Kiang West
comprises 750 km2 of savannah scrub and is bordered on 3 sides
by the River Gambia and its tributaries and on the fourth by
a partially surfaced road. The population consists of w14,000
individuals, predominantly ethnic Mandinka, who live by sub-
sistence farming. Nutritional status and morbidity patterns in
this community have been well described and are largely defined
by a distinct tropical seasonality, with a long dry season from
November to June followed by a period of intense and daily
rainfall between July and October (17–19). Local HIV sero-
prevalence at the time of the study was w1% (20). In this area,
the incidence of low birth weight was 13%, PTB was 12%, and
25% of newborns were small for gestational age (,10th centile
weight for gestational age) with FGR (18).
Local maternal and child primary health care is provided by
government nurse trekking teams, supported by the clinical staff
of MRC Keneba. Most women deliver at home under the su-
pervision of traditional birth attendants (TBAs) who undergo
basic training in clean birth practices and recognition of common
pregnancy complications (21). Secondary and tertiary health care
services are provided at the Royal Victoria Teaching Hospital
(RVTH) in Banjul, which is 4 h by road from Keneba.
Selection of subjects
Women aged 17–45 y and residing in Kiang West during the
recruitment phase of the study and who were registered in the
MRC Keneba demographic database and not concurrently en-
rolled in other intervention studies were eligible to take part in
the trial. Eligible women (and their guardians for those ,18 y
old) were invited to attend a recruitment clinic in their home
villages. They were provided with oral and printed study in-
formation by a nurse-midwife (NM) and asked to give written
consent if they wished to take part. Those who used no con-
traception, were not known to be pregnant, and had experienced
menses in the past 3 mo and were not breastfeeding were in-
cluded. Those who were severely anemic (hemoglobin concen-
tration ,7 g/dL) were treated before being considered for
re-recruitment at a later date. Women with a subsequent multiple
pregnancy or obvious fetal abnormality were excluded, although
they were clinically followed because nonnutritional factors de-
termine placental function in such pregnancies (22).
Randomization
Eligible subjects identified in the demographic survey were
randomly assigned before recruitment to 1 of 4 color-coded
groups. An independent researcher allocated 2 color codes to
intervention and 2 to placebo groups and held the allocation key.
Randomization was completed by an MRC Keneba statistician
(AJF) by using computer-generated permuted blocks of 8,
stratified by maternal age. Researchers involved in recruitment,
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data collection, or analysis were blind to subjects’ color codes,
and all staff and participants were blind to the allocation key.
Recruitment
The NM recorded a brief obstetric, medical, and educational
history and collected a 10-mL venous blood sample from each
participant (Sarstedt Monovette). Whole blood was analyzed for
hematology and the presence of malaria parasites. Plasma was
separated within 4 h of venipuncture, frozen at 2808C, and later
analyzed for vitamin A and ferritin concentrations. Weight,
height, left midupper arm circumference (MUAC), and systolic/
diastolic blood pressure were measured by a trained fieldworker.
Women were issued tablets corresponding to their randomized
color-coded intervention group and were asked to take 1 tablet
daily until told to stop by a member of the trial team.
Supplementation
Participants were seen at least fortnightly by a fieldworker in
their village and were resupplied with tablets according to their
color groups. The number of tablets apparently consumed be-
tween visits was used as a measure of compliance (compliance =
number of tablets apparently consumed/number of days enrolled
in study). Information on morbidity and menstrual patterns was
recorded. Women were asked to notify fieldworkers of missed
menstrual periods and to provide urine samples for pregnancy
testing by an NM when pregnancy was suspected (QuickVue
One-Step hCG Urine Test; bioMérieux). With a positive
pregnancy test result, the woman’s study intervention was
withdrawn and replaced with 60 mg elemental iron and 250 mg
folic acid daily, in accordance with Gambian national antenatal
policy. These women were referred to the study antenatal clinic
(ANC) at MRC Keneba for pregnancy confirmation and follow-
up. Those without a positive pregnancy test result continued
with supplementation until July 2007 (a period of 12–14 mo), at
which time the supplementation was discontinued. Hematologic
outcomes for nonpregnant participants are reported elsewhere
(23). Women who migrated from the study area for 6 consecu-
tive weeks were defined as lost to follow-up. Fetal deaths were
classified as miscarriages (spontaneous loss of pregnancy before
24 completed weeks of gestation) or stillbirths (no signs of life
at birth after 24 completed weeks of gestation). These were
reported by TBAs and cross-checked by the fieldworker and/or
the NM. In cases of uncertainty, confirmatory sonography and
urinary pregnancy testing were completed at the ANC in MRC
Keneba.
Pregnancy follow-up
Viable pregnancy was confirmed and dated by using trans-
abdominal ultrasound at the ANC booking clinic. Women
without a viable pregnancy at the ANC were assumed to have
miscarried and were censored from the study. Women with
multiple pregnancies or fetal anomalies were also censored. All
women were offered continuing clinical care, and those who
required specific obstetric management were referred to RVTH.
Women with sonographically dated singleton pregnancies
were invited and offered transport to attend the ANC for complete
clinical review at 18–22 wk and 28–32 wk, including anthro-
pometric measurements, urinalysis, blood pressure assessment,
external obstetric examination, detailed fetal sonography, and
venipuncture. These tasks were completed by the NM, and so-
nography was completed by one of the authors (SO). Pregnan-
cies of .24 wk of gestation at booking could not be accurately
dated by ultrasound and were dated by maternally recalled last
menstrual period (LMP). Because maternally recalled LMP is
imprecise in this population (24), a restricted analysis of de-
livery outcomes alone was used for this subgroup.
At ANC booking, a 5-mL blood sample was drawn and
analyzed for hemoglobin concentration, presence of malaria
parasites, and syphilis serology. As required by the Gambian
Government Ethics Committee, each subject was offered sero-
logic testing for HIV, with pre- and posttest counseling. HIV-
positive participants were referred to the MRC HIV clinical
service in Fajara. Women who delivered before attendance at the
HIV clinic were offered maternal and infant nevirapine pro-
phylaxis, in keeping with the national guideline at the time.
An uncuffed 10-mL venous blood sample was drawn at the 18–
22-wk and 28–32-wk review. Aliquots were prepared, stored,
and analyzed within 1 h of venipuncture, as described for re-
cruitment samples, except for ferritin concentration, which was
not measured at 18–22 wk. Additional aliquots of chilled citrate-
plasma aliquot and serum were analyzed for PAI-1 and PAI-2
concentrations and placental hormones [human prolactin (hPL)
and human chorionic gonadotropin (hCG)], respectively. The
subject was given directly observed intermittent preventative
treatment with sulfadoxine-pyrimethamine at 18–22 wk and 28–
32 wk.
TBAs reported impending deliveries to their local resident
fieldworker. A 10-mL cord blood sample taken from a large vein
on the fetal side of the placenta of live-born infants. The placenta
was transported as soon as it was collected to MRC Keneba,
cleaned, the membranes trimmed, and the cord cut close to its
insertion. Placental weight was recorded to the nearest 10 g by
using a digital balance. Cord serum and whole-blood aliquots
were prepared. The concentration of cord serum MMA was
measured. Whole blood was analyzed for hematologic variables
and the presence of malaria parasites.
Within 72 h of delivery, an NM examined the mother and
infant. Maternal weight, MUAC, urinalysis, and blood pressure
were recorded. An uncuffed 10-mL venous blood sample was
drawn from the mother and aliquots prepared and analyzed as
for the cord samples. Neonatal anthropometric measurements
were recorded. Dubowitz scoring was conducted to improve the
detection of preterm infants, as part of standard clinical risk
assessment.
Measurements
Maternal height, weight, MUAC, and blood pressure were
measured by pairs of fieldworkers at recruitment and by 1 of
2 NMs at scheduled antenatal visits and at delivery. Standard
techniques were used for each measurement. Weight was mea-
sured (to the nearest 0.1 kg) by using daily calibrated, digital
scales (Tanita Corporation). Height (to the nearest 0.1 cm) was
measured by using a daily calibrated stadiometer (Leicester
height measure; Seca) and BMI was estimated [weight (kg)/
height (m)2]. Underweight was defined as a BMI (in kg/m2)
,18.5. MUAC (to the nearest mm; left arm) was measured with
graduated tapes (Henley Medical Supplies). Triplicate blood
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pressure was measured (automated Omron 705IT device; Om-
ron) and measurements replicated to within 5 mm Hg. Hyper-
tension was defined as systolic blood pressure .139 mm Hg or
diastolic blood pressure .89 mm Hg.
Neonatal anthropometric measurements were performed by 1
of 2 NMs. Birth weights were measured (to the nearest 20 g) with
sling and portable spring balances (CMS Weighing Equipment),
and these were regularly checked with standard weights. Birth
length (to the nearest 5 mm) was measured by using neonatal
length mats (TALC Teaching Aids). Head circumference (to
the nearest mm) was measured with graduated tapes (Henley
Medical Supplies). Fieldworkers and NMs were trained and
cross-compared in anthropometric techniques as part of their
employment induction with the MRC, which was repeated at the
start of this study. Refresher training was undertaken regularly.
Hemoglobin measurements at pregnancy booking used a
hemoglobinometer (HemoCue B). Analyses on venipuncture
samples included hemoglobin concentration, white blood cell
count, mean cell volume, mean cell hemoglobin, and reticulocyte
count (Cel-Dyn 3700 Analyzer; Abbott Diagnostics). Anemia
was defined as hemoglobin ,12 g/dL in nonpregnant women
and ,11 g/dL in pregnant women. Malaria blood films were
prepared and stained with Giemsa stain, and 100 high-power
microscopic fields were examined to determine parasite count
against 200 white blood cells. PAI-1 and PAI-2 antigen con-
centrations were measured with mouse-monoclonal antibody–
based ELISAs (Elitest; Hyphen-BioMed) as was MMA in
maternal and fetal blood (IBL International), hPL, and hCG
(Addenbrookes Hospital).
Vitamins A and E were measured by HPLC (25). Vitamin A de-
ficiency was defined as a serum retinol concentration,0.7 mmol/L
and vitamin E deficiency as a serum a-tocopherol concentra-
tion ,12 mmol/L. Ferritin was measured by instrumental immu-
noassay (Dimension Xp; Siemens). Iron deficiency was defined as
a plasma ferritin concentration ,15 mg/L.
Obstetric sonography was conducted by one of the authors
(SO) who had certified training in standard methods (25). The
ultrasound machine was an ACUSON Antares with a CH6-2
(5.71-MHz) transducer (Siemens). Gestational age was derived
from sonographic measurement of the fetal crown-rump length or
biparietal diameter. At the 18–22-wk and 28–32-wk review, fetal
biometry and utero-placental blood flow were assessed by so-
nography and Doppler velocimetry of the right and left uterine
arteries (UtAs), umbilical artery, and fetal middle cerebral artery
(MCA) waveforms. The resistance and pulsatility indexes were
calculated for each vessel and for the peak systolic velocity (PSV)
of the MCA. The presence of diastolic “notching” in either of the
UtAs was recorded. A mean UtARI.0.55 and bilateral notching,
or a mean UtARI .0.65 and unilateral notching, were defined as
“high resistance” waveforms (26). Women with high-resistance
waveforms were monitored for pre-eclampsia and/or FGR and,
if necessary, referred to RVTH. Intraobserver variation in so-
nographic variables was not estimated.
Statistical analysis
We estimated that a sample of 200 women in each arm of the
trial would generate 90% power to detect a 20% difference in the
mean PAI-1 to PAI-2 ratio at 18–22 wk of gestation between
supplementation groups at a 5% level of significance. This was
based on variance parameters (population mean ratio: 0.40; SD:
0.23) drawn from a trial of antioxidant vitamin supplementation
in British women at risk of pre-eclampsia (27) and allowed for
10% loss to follow-up. This sample size had 90% power to detect
a change in mean UtARI equivalent to 0.35 SDs at the 5% sig-
nificance level [assuming a mean UtARI of 0.30; SD: 0.01 (26)].
To detect a difference in mean MMA transplacental transfer
ratio of 0.1, with 90% power at the 5% level of significance,w80
mother-infant pairs were required in each arm of the trial, as-
suming a mean transfer ratio of 1.01 and an SD of 0.18 (28). It
was considered that this sample size would be readily available
within the main pregnancy cohort.
On the basis of MRC Keneba demographic survey data, we
assumed that 16% of women aged between 17 and 45 y in this
community would conceive in any given year. This suggested that
at least 2400 women would be required over the course of the
study to satisfy the largest estimate of required sample size, 400
pregnancies. We identified 3206 eligible subjects in the survey.
Data were double-entered into a computerized database
(MS-Access; Microsoft) and verified within 48 h of collection.
Scheduled data validation checks were made. A copy of the raw
data set was maintained with the MRC data management team.
All available data on singleton pregnancies without fetal
anomalies were included and analyzed according to the original
randomization. Every effort was made to complete the data set for
each subject, but specific outcomes on individual subjects were
occasionally unavailable (e.g., on women who had withdrawn
their consent, migrated out of the study area, or otherwise failed
to attend within the predefined timeframe of a particular end-
point). In these cases, the remaining data were included in all
other analyses. Continuous data were analyzed by using linear
regression, assuming equal variance. Outcomes were regressed
on a single predictor, trial arm. To improve the precision of
primary analyses, multiple regression was used to adjust for the
effects of gestational age at point of sampling, because gesta-
tional age is an a priori predictor of all pregnancy outcomes.
Evidence for interaction between treatment effect and gestational
age at point of sampling was also sought for primary outcome
measures. Continuous data that were not normally distributed
were log-transformed before analyses of their geometric means.
Those that were not rendered normally distributed by this
transformation were analyzed by using nonparametric tests.
Binary responses were analyzed by logistic regression. Data
collected on the same individuals at $2 time points were ana-
lyzed by using random-effects models fitted by generalized least
squares.
Although the study was not powered for subgroup analyses, we
went on to assess treatment effects on the primary outcomes by
season of conception (wet-hungry compared with dry-harvest) by
fitting a season 3 treatment interaction term into the models.
This stratification was justified as an exploratory analysis on the
basis of previous data showing that PTB and small-for-gestational-
age birth show strongly divergent patterns of seasonality in Kiang
West (18). Significance was set at P , 0.05. Statistical analyses
were carried out by using Stata 9.1 (StataCorp).
Medical management
All women and their infants were offered free routine clinical
services, including infant vaccinations. Transport was provided
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by MRC ambulance. Malaria parasitemia was treated with chlo-
roquine or quinine and sulfadoxine-pyrimethamine in accordance
with national policy. Pre-eclampsia was defined by a gestational
systolic blood pressure .140 mm Hg or a diastolic blood
pressure .90 mm Hg in a previously normotensive woman, in
conjunction with dipstick proteinuria. Women with pre-eclampsia
were referred to RVTH for further management.
Ethics
This trial was approved by the Scientific Coordinating Com-
mittee of MRC Laboratories, The Gambia, and by the MRC/
Gambian Government Ethics Committee (L2005.111v2 SCC
1000). An independent trial monitor and data safety and moni-
toring board assessed trial activity at regular intervals, under the
auspices of Good Clinical Practice guidelines (29). MRC Keneba
offers free primary health care in collaboration with the Gambian
Government Lower River Divisional Health Team. Apart from
the structured clinical contacts outlined (during which subjects
were given transport and a meal), no additional benefits were
provided to trial participants. The trial was registered as ISRCTN
13687662 (www.controlled-trials.com/isrctn/pf/13687662).
RESULTS
Characteristics of study population
The study profile [CONSORT (Consolidated Standards of
Reporting Trials) diagram] is shown in Figure 1. After pre-
screening the demographic surveillance database, we identified
and randomly assigned 3206 women who were eligible for in-
clusion in the trial on the basis of age, residency, and lack of
involvement in other intervention studies. Of these, 2189 (68.2%)
FIGURE 1 CONSORT (Consolidated Standards of Reporting Trials) diagram. UNIMMAP, UNICEF/WHO/United Nations University international
multiple micronutrient preparation.
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attended a recruitment clinic to be screened for exclusion criteria
from March to May 2006 (n = 1337), May–June 2006 (n = 610),
and June–July 2006 (n = 242). We recruited 1156 women, 567
(49%) in the UNIMMAP arm and 589 (51%) in the placebo arm.
Reasons for exclusion included refusal to consent (n = 50), known
or suspected pregnancy (n = 205), breastfeeding an infant (n =
362), failure to menstruate in the previous 3 mo (n = 393), and use
of depot contraception (n = 23). Two women were withdrawn
because they were later discovered to be in late pregnancy, having
booked for standard antenatal care before recruitment, and one
pregnant woman withdrew consent.
The median age of participants was 28.8 (IQR: 21.7–36.7) y,
and 213 (18.4%) were teenagers. Most were illiterate; 936 (81.0%)
had never attended primary school. Parity ranged between 0
and 14, and 294 women were nulliparous (25.4%). A history of
pre-eclampsia was elicited from 3.1%, and 22.7% reported
a previous pregnancy loss. Overall, 14.8% were underweight
and 44.2% iron deficient. The prevalence of anemia (hemo-
globin ,12 g/dL) was 50.5%, with 0.6% who were severely
anemic (hemoglobin ,7 g/dL). Almost all of the women
(97.2%) reported sleeping under a bed net the previous night.
The prevalence of malaria parasitemia was 0.9%. Vitamin A
deficiency occurred in 4.0% and vitamin E deficiency in 1.2%
of women.
There were 11 women who were excluded after the late
identification of exclusion criteria, 14 withdrew without giving
a reason, 78 nonpregnant women migrated from the study area,
and 3 women died. Those lost to follow-up during supplemen-
tation (n = 106) were younger than the remaining women (n =
1050) [23.0 (IQR: 19.0–29.8) compared with 29.7 (IQR: 21.9–
36.8) y; P , 0.001], were less likely to have children (50.0%
compared with 77.1%; OR: 0.30; 95% CI: 0.20, 0.45; P ,
0.001), and more likely to have schooling (42.5% compared
with 16.7%; OR: 3.69; 95% CI: 2.43, 5.60; P , 0.001). There
were no differences in baseline nutritional characteristics.
Supplementation
There was no difference in participant attendance frequency at
supplementation clinics between women in the 2 study arms
[UNIMMAP: 72% (IQR: 50–85%); placebo: 71% (IQR: 48–85%;
P = 0.307, Wilcoxon’s rank-sum test]. On the basis of tablet
counts, intervention compliance was 88% (IQR: 65–100%) in the
UNIMMAP arm compared with 86% (IQR: 63–100%) in the
placebo arm (P = 0.158, Wilcoxon’s rank-sum test).
Pregnancy booking
There were 486 women with positive pregnancy tests during
the study. The baseline characteristics of these women were
similar in both arms of the trial, although more women in the
placebo arm had undergone secular schooling (Table 1).The
median time with supplementation before the generation of
a positive pregnancy test was 24.1 wk (IQR: 13.1–43.1), with no
difference between study arms (P = 0.943). Pregnancies were
clinically confirmed in 203 of 567 (35.8%) of those receiving
UNIMMAP and 212 of 589 (36.0%) of those receiving placebo.
It was not possible to differentiate early miscarriages from false-
positive pregnancy test results for 68 women who resumed
menstruation before clinical confirmation of pregnancy. However,
there was no difference in the odds of unconfirmed pregnancy
between arms (OR for UNIMMAP: 1.04; 95% CI: 0.63, 1.74;
P = 0.868).
Of 415 clinically confirmed pregnancies, 312 were dated
sonographically, 88 were dated by LMP, and 15 were undated. On
the basis of dating assessments, 105 women were pregnant at
recruitment (range: 0–16.4 wk of gestation; median: 5.1 wk).
For dated pregnancies, the median time with preconceptional
supplementation was 10.9 wk (IQR: 20.3 to +29.4) and with
postconceptional supplementation was 11.0 wk (IQR: 7.9–15.8),
which did not differ between arms in either period (P = 0.922
and 0.428, respectively). Of 295 pregnancies conceived while
receiving supplementation, there was no difference in concep-
tion rates with UNIMMAP or placebo (HR for UNIMMAP:
0.94; 95% CI: 0.75, 1.18; P = 0.613). There were 8 twin preg-
nancies (3 UNIMMAP, 5 placebo).
Placental vascular-endothelial function
There were 333 women who booked with a singleton preg-
nancy on or before 24 wk of gestation by antenatal ultrasound. Of
TABLE 1
Baseline characteristics of participants who later returned positive
pregnancy tests1
UNIMMAP (n = 239) Placebo (n = 247)
Variable n Value n Value
Maternal age, y 239 28.8 (23.7–36.7)2 247 28.9 (23.7–34.8)
Secular schooling, n (%) 239 29 (12.1) 247 46 (18.6)3
Nulliparity, n (%) 239 26 (10.9) 247 25 (10.1)
History of pre-eclampsia,
n (%)
239 6 (2.5) 247 6 (2.4)
History of pregnancy loss,
n (%)
239 58 (24.3) 247 66 (26.7)
BMI, kg/m2 239 20.7 (19.3–22.9) 247 20.9 (19.4–23.3)
Underweight,4 n (%) 239 34 (14.2) 247 30 (12.2)
Stunted,5 n (%) 239 6 (2.5) 247 15 (6.1)
Blood pressure,6 mm Hg 239 107 (100–115) 246 108 (101–114)
Retinol, mmol/L 236 1.09 (0.90–1.33) 241 1.16 (0.97–1.36)
Vitamin A deficiency,7
n (%)
236 11 (4.7) 241 5 (2.1)
a-Tocopherol, mmol/L 236 20.0 (17.6–23.8) 241 20.8 (17.2–24.0)
Vitamin E deficiency,8
n (%)
236 6 (2.5) 241 2 (0.8)
Ferritin, mg/L 235 17.3 (9.8–28.6) 240 16.9 (9.9–31.3)
Iron deficiency,9 n (%) 235 78 (33.2) 240 76 (31.7)
Hemoglobin, g/dL 238 11.9 (10.9–12.6) 245 12.0 (11.1–12.8)
Anemia,10 n (%) 238 124 (52.1) 245 121 (49.4)
CRP, mg/L 235 0.7 (0.3–1.5) 240 0.6 (0.3–1.3)
Malaria, n (%) 232 2 (0.9) 240 3 (1.3)
1CRP, C-reactive protein; UNIMMAP, UNICEF/WHO/United Nations
University international multiple micronutrient preparation.
2Median; IQR in parentheses (all such values).
3Pearson chi-square = 0.1694, P = 0.048.
4BMI ,18.5.
5Height ,151.8 cm.
6Systolic blood pressure.
7Retinol ,0.7 mmol/L.
8a-Tocopherol ,12 mmol/L.
9Ferritin ,12 mg/L.
10Hemoglobin ,12 g/dL.
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these, 262 agreed to attend for measurement of the primary
endpoint at 18–22 wk. There was no difference in PAI-1 or PAI-2
concentrations, or their ratios, between women in either arm
(Table 2). Similarly, the geometric mean PAI-1 to PAI-2 ratio at
28–32 wk was 0.053 in the UNIMMAP arm (n = 125) and 0.052
in the placebo arm (n = 130) (difference: +1.6%; 95% CI:
213.6%, +16.9%; P = 0.832). Adjustment for gestational age at
the point of sampling did not change the effect of supplemen-
tation on PAI ratio over the course of pregnancy and there was
no evidence of any interaction between treatment effect and
gestational age at the point of sampling (P = 0.554).
Women taking UNIMMAP had a reduced UtARI (P = 0.0499)
and UtAPI (P = 0.025) compared with women taking placebo at
18–22 wk of gestation (Table 3). The PSV in the fetal MCAs
was also slower in the UNIMMAP arm (P = 0.035), but there
were no differences in the indexes of blood flow in the umbilical
arteries.
There were 297 women who underwent at least one Doppler
study between 18 and 32 wk of gestation. After adjustment for
gestational age at the time of measurement, UNIMMAP supple-
mentation reduced the UtARI by a mean of 0.02 units compared
with placebo over the course of the pregnancy (18–32 wk) (95%
CI: 20.03, 20.00; P = 0.040; n = 297; 526 observations). There
was no evidence of any interaction between treatment effect and
gestational age at the point of sampling (P = 0.831). In the
UNIMMAP arm of the trial, 3 of 129 (2.3%) women had high-
resistance Doppler waveforms in the uterine arteries at 28–32 wk
of gestation compared with 7 of 136 (5.2%) women in the placebo
group (OR: 0.44; 95% CI: 0.11, 1.73; P = 0.228).
Placental transfer capacity
UNIMMAP supplementation had no effect on MMA transfer
ratio at delivery compared with placebo (95% CI: 28.4, +22.0;
P = 0.379; n = 231). Adjustment for gestational age at the point
of sampling did not affect this finding, and there was no evidence
of any interaction between treatment effect and gestational age
at the point of sampling (P = 0.730). There were no differences
in fetal anthropometric indexes between the groups at either of
the antenatal time points (data not shown).
Stratification of primary outcomes by season of conception
There were no significant interactions between effects of
seasonality of conception and supplementation on the primary
outcomes (PAI ratio: P = 0.654; UtARI: P = 0.340; placental
transfer ratio: P = 0.597). Pregnancies conceived in the hungry
season were associated with a 27.4% decline in transplacental
transfer ratio of MMA (95% CI: 10.8, 44.0; P = 0.001), in-
dependently of gestational age at delivery and supplementation
arm. Seasonality had no independent effects on the other pri-
mary outcomes (data not shown).
Placental endocrine function
There were no differences in geometric mean hCG and hPL
concentrations at 18–22 wk of gestation between the arms of the
study—hCG: 14.9 (95% CI: 13.1, 17.0) mg/mL in the UNIMMAP
group (n = 116) compared with 14.9 (95% CI: 13.3, 16.8) mg/mL
in the placebo group (n = 137) (P = 1.000); hPL: 2.52 (95% CI:
2.40, 2.66) mg/mL in the UNIMMAP group compared with 2.66
(95% CI: 2.51, 2.82) mg/mL in the placebo group (P = 0.179).
Birth outcomes
There were 10 confirmed pregnancies with unknown outcomes
because of migration or withdrawal before delivery (3 UNIMMAP,
7 placebo). Of 8 twin pregnancies, one in the placebo arm ended
in a discordant fetal death. Of singleton pregnancies with known
outcomes, 13 of 197 (6.6%) in the UNIMMAP arm and 8 of
200 (4.0%) in the placebo arm ended in fetal death (OR: 1.70;
95% CI: 0.69, 4.19; P = 0.252). One fetal death in the placebo
group was associated with a maternal death.
Fewer male infants were born to women taking UNIMMAP
than to those taking placebo (48.4% compared with 57.8%; P =
0.07). The study was not powered to assess the effect of sup-
plementation on neonatal anthropometric measurements, and
there were no differences in birth weight, length, head circum-
ference, or placental weight between the groups, before or after
adjustment for gestational age at delivery (data not shown).
Gestational age distribution at delivery was skewed. Median
gestation was 40.3 wk (IQR: 38.7–41.1 wk) in the placebo group
and 40.0 wk (IQR: 38.9–41.1 wk) in the UNIMMAP group (P =
0.669). However, 10 of 177 (5.6%) infants were born preterm in
the UNIMMAP arm compared with 23 of 190 (12.1%) in the
placebo arm (OR: 0.43; 95% CI: 0.20, 0.94; P = 0.035). Among
ultrasound-dated pregnancies, 8 of 150 (5.3%) live-born infants in
the placebo arm were preterm compared with 1 of 139 (0.7%) in
the UNIMMAP group (OR: 0.13; 95% CI: 0.02, 1.04; P = 0.055).
Maternal and neonatal adverse events
There were 423 of 567 women (74.6%) in the UNIMMAP arm
of the study who reported at least one adverse event compared
with 442 of 589 (75.0%) in the placebo arm (OR: 0.94; 95% CI:
0.72, 1.23; P = 0.671). Common general complaints included
gastrointestinal disturbances, skin and eye problems, respiratory
TABLE 2
Maternal PAI concentrations and ratio at 18–22 wk of gestation by allocation1
UNIMMAP (n = 119) Placebo (n = 139)
Difference estimate
(95% CI), % PVariable n Geometric mean (95% CI) n Geometric mean (95% CI)
PAI-1, ng/mL 119 21.7 (19.8, 23.7) 139 21.0 (19.5, 22.7) +3.0 (28.6, +14.7) 0.606
PAI-2, ng/mL 119 332.2 (200.7, 366.9) 138 330.1 (301.6, 361.7) +0.6 (212.8, +13.9) 0.935
PAI-1:PAI-2 119 0.07 (0.06, 0.07) 138 0.06 (0.06, 0.07) +2.6 (213.3, +18.6) 0.746
1Significance was assessed by multiple linear regression, adjusted for gestational age. PAI, plasminogen activation
inhibitor; UNIMMAP, UNICEF/WHO/United Nations University international multiple micronutrient preparation.
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and urinary tract infections, and dental caries/abscesses. The
prevalence of common complaints did not differ between the
groups. Among women with positive pregnancy tests, 6 of 168
(3.6%) taking UNIMMAP and 3 of 181 (1.7%) taking placebo
had a positive malaria film during antenatal or perinatal review
(OR: 2.20; 95% CI: 0.54, 8.90; P = 0.271). Pre-eclampsia was
detected in 4 of 203 women (2.0%) in the UNIMMAP arm and
3 of 212 (1.4%) in the placebo arm (OR: 1.40; 95% CI: 0.31,
6.34; P = 0.662). At delivery 11 of 177 (6.2%) in the UNIMMAP
arm were hypertensive compared with 10 of 186 (5.4%) in the
placebo arm (OR: 1.16; 95% CI: 0.48, 2.82; P = 0.733).
Neonatal mortality data were available for 325 of 376 (86.4%)
live-born singleton infants. There were 5 neonatal deaths in 160
births (3.1%) in the UNIMMAP arm and 4 neonatal deaths in 165
births (2.4%) in the placebo arm (OR: 1.30; 95% CI: 0.34, 4.92;
P = 0.701). Three nonpregnant women died of unknown causes
(2 UNIMMAP, 1 placebo), and one pregnant woman receiving
placebo died after antepartum hemorrhage.
DISCUSSION
To our knowledge, this is the first trial to assess the impact of
periconceptional micronutrient supplementation on placental
function. Women who took UNIMMAP during early pregnancy
had lower uterine vascular resistance indexes than those who took
placebo, but this effect was not mediated through a detectable
change in placental endothelial function and did not affect trans-
placental transfer capacity, placental endocrine function, rates of
fetal growth, or birth outcomes.
We observed no effect of micronutrient supplementation on the
midgestational plasma concentrations of PAI-1 or PAI-2 or their
ratio. Because the sample size required to assess a 20% change in
this outcome was not achieved, we cannot exclude the possibility
of a type II error in our analysis. However, given the CIs of the
sample distribution of PAI ratios, other explanations for a null
effect are more plausible. In the previous trial, urban British
women at high risk of pre-eclampsia who were supplemented
with pharmaceutical doses of vitamins C (1000 mg/d) and
E (400 IU/d) had a 21% reduction in PAI-1:PAI-2 compared with
those taking placebo (27). We supplemented rural Gambian
women, in whom the incidence of pre-eclampsia was particularly
low (1–2%), with the Recommended Dietary Allowances of 15
micronutrients. The geometric mean PAI ratio in our sample
remained small throughout pregnancy as a function of low
systemic endothelial activation, making it a poor discriminator
of placental function in our population.
Periconceptional UNIMMAP supplementation reduced the
indexes of uterine-artery vascular resistance (UtAPI and UtARI;
effect sizew0.25 SD). The effects were small and of no clinical
significance, but they support our hypothesis that periconceptional
micronutrient status can modulate placental vascular function.
In early pregnancy the uterine-artery Doppler waveform is
characterized by a high-resistance profile, transforming to one of
low resistance by 24 wk of gestation in normal pregnancies. The
persistence of high-resistance waveforms is predictive of sub-
sequent pre-eclampsia, FGR, and placental abruption (30). In
a large Dutch cohort, self-reported periconceptional folic acid
supplementation was associated with lower utero-placental vas-
cular resistance, although the effect was also small (31). Folic
acid could facilitate the epigenetic modulation of early placental
growth by acting as a methyl donor during the wave of DNA
methylation that takes place shortly after conception (32). In a
small subset of women from this study we showed that peri-
conceptional UNIMMAP supplementation led to differential cord
blood methylation patterns assessed by using both candidate gene
(33) and genome-wide (34) approaches.
Supplementation also reduced fetal middle cerebral PSV (effect
size w0.33 SD), an inverse marker of fetal hemoglobin concen-
tration (26). By delivery, cord hemoglobin concentrations were
similar in both groups, but the effect of prenatal UNIMMAP
supplementation on other indexes of neonatal erythropoiesis is
unknown.
Periconceptional UNIMMAP supplementation had no effect
on transplacental transfer of MMA. We are unaware of other
studies that used transfer ratios to assess the impact of nutritional
interventions on placental transport function. Experimental work
in sheep and rats suggests that general periconceptional un-
dernutrition reduces the expression of transporter proteins in the
placenta and the rate of nutrient delivery to the fetus (35).
Similarly, we observed that conception in the “wet-hungry”
season (a period of nutritional austerity) predicted substantially
reduced MMA ratios and birth weights.
TABLE 3
Doppler velocimetry indexes at 18–22 wk of gestation by allocation1
UNIMMAP (n = 121) Placebo (n = 140)
Difference estimate
(95% CI) Pn Mean 6 SD n Mean 6 SD
Uterine arteries
PI 121 1.12 6 0.29 140 1.20 6 0.31 20.08 (20.16, 20.01) 0.025
RI 121 0.61 6 0.08 140 0.63 6 0.08 20.02 (20.04, 20.00) 0.050
Umbilical artery
PI 120 1.36 6 0.20 139 1.38 6 0.20 20.01 (20.06, +0.04) 0.631
RI 120 0.74 6 0.07 139 0.74 6 0.06 20.00 (20.02, +0.01) 0.906
Middle cerebral artery
PI 87 1.41 6 0.18 102 1.46 6 0.22 20.05 (20.12, +0.01) 0.097
RI 87 0.74 6 0.07 102 0.76 6 0.08 20.02 (20.04, +0.00) 0.068
PSV, cm/s 85 28.2 6 4.43 102 29.8 6 5.31 21.54 (22.96, 20.11) 0.035
1Significance was assessed by multiple linear regression adjusted for gestational age. PI, pulsatility index; PSV, peak
systolic velocity; RI, resistance index; UNIMMAP, UNICEF/WHO/United Nations University international multiple micro-
nutrient preparation.
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Few trials have assessed neonatal anthropometric measurements
and pregnancy outcomes with periconceptional micronutrient sup-
plementation (5). We did an exploratory investigation of these
outcomes as well as a stratified analysis by season. Within the
limits of our sample size, we found no significant differences in any
of the birth data between the arms of the trial. There were fewer
PTBs in the UNIMMAP group, a finding that is consistent with
previous observational studies (36, 37), but the number was small,
the CI around the effect estimate was wide, and there was no
overall change in the median duration of gestation between the
groups. Caution is therefore required in the interpretation of this
result, which might be a chance finding. Although seasonality was
anticipated to be an important effect modifier in the current trial
(18), there was no evidence for a differential effect of supple-
mentation on pregnancies conceived during thewet-hungry season.
Previously, maternal hemoglobin concentration in early preg-
nancy (although not ferritin concentration) was negatively as-
sociated with plasma concentrations of hCG and hCL (38). We
found no effect of periconceptional UNIMMAP supplementation
on midpregnancy production of these placental hormones.
Strengths and weaknesses of the study
Our study is a novel and detailed investigation of placental
function in a rural African populationwith lowHIV seroprevalence
but high rates of anemia; the findings are likely to extrapolate to
similar populations elsewhere. Strict eligibility screening ensured
that most women conceived after a lengthy period of receiving
supplementation. There was enthusiastic community participation
in the trial, and close integration of staff with the study population
ensured high compliance with supplementation and good clinical
oversight. Pregnancy dating was robust for the majority of the
women and was based on ultrasound assessment.
Because only 258 of the 3206 women who were pre–randomly
assigned (8%) to supplementation are included in the analysis of
the primary outcome, protection from bias afforded by the
randomization cannot be assumed. Table 1 suggests that of those
women who conceived during the trial and were therefore eli-
gible for analysis, more of those in the placebo arm had accessed
secular education, although there were no other significant dif-
ferences identified. There was a loss of data from migration and
late booking for antenatal care. Women in traditional societies
often delay pregnancy disclosure (39), and 37% of women with
a confirmed pregnancy failed to attend the primary endpoint at
18–22 wk of gestation. The resulting loss of power was reflected
in the wide CIs around the small increase in PAI-1:PAI-2, esti-
mated with UNIMMAP at 18–22 wk.
Malaria was a potential effect modifier in our study, and we did
not examine placental histology to assess this in detail. There was
no evidence for a differential effect of supplementation in the wet
season, all women had directly observed intermittent preventative
treatment for malaria, and rates of peripheral parasitemia were
very low throughout the study, suggesting a limited impact from
this infection.
Conclusions
Experimentally, our data suggest that placental vascular func-
tion may be modifiable by periconceptional nutritional supple-
mentation in humans, but the therapeutic and public health
implications of this finding are unclear. Previously reported ef-
fects of prenatal MMS on fetal growth are unlikely to have been
mediated through measurable changes in placental vascular, en-
dothelial, transport, or endocrine functions but rather via alter-
native mechanisms (40).
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